Disclosures: Muhammad Atif Zahoor: Nothing to Disclose, Nahla Fadlelmawla: Nothing to Disclose, Adrian Kuipery: Nothing to Disclose, Joshua Feld: Nothing to Disclose, Alexander Mosa: Nothing to Disclose, Adam Gehring: Nothing to Disclose, Jordan Feld: Mirum: Consultant, AbbVie, Bluejays, Gilead, Janssen, GSK, Roche, VIR Roche: Consultant, Bluejays: Consultant, Gilead: Consultant, Janssen: Consultant, GSK: Consultant, Roche: Consultant, VIR Biotechnology: Consultant, Altimmune, AbbVie, Gilead, Jannsen, GSK, Roche, VIR Bio: Grant/Research Support 383 TENOFOVIR ALAFENAMIDE FUMARATE IN TREATMENT-NAVE CHRONIC HEPATITIS B PATIENTS WITH LIVER FIBROSIS: A PRELIMINARY NON-INVASIVE RESULTS OF 96 WEEKS Jialing Zhou 1 Xiaoning Wu 1 chuanwu zhu 2 Jiming Zhang 3 Ping Li 4 Tao Han 5 huiguo ding 6 Chenghai Liu 7 Wen Xie 8 Qing Xie 9 Yali Zong 10 Hong You 11 Jidong Jia 12 , 1 Beijing Friendship hospital, Capital medicine university, 2 The Fifth Peoples Hospital of Suzhou, China, 3 Huashan Hospital, Shanghai Medical College, Fudan University, China, 4 Tianjin Second Peoples Hospital, China, 5 Tianjin Medical University, Tianjin Union Medical Center, 6 Beijing Youan Hospital, Capital Medical University, China, 7 Shanghai Traditional Chinese Medicine Hospital, 8 Beijing Ditan Hospital, Capital Medical University, Beijing, China, 9 Ruijin Hospital, 10 The Ninth Hospital of Nanchang, China, 11 Capital Medical University, 12 Beijing Friendship Hospital, Capital Medical University, China Background: To investigate the antifibrotic efficacy and safety of tenofovir alafenamide (TAF) in treatment-nave chronic hepatitis B (CHB) with liver fibrosis
They also confirmed that 63 of 175 chemicals of concern were present in the human body, and most lacked safety data
Is there an alternative product?
Look at the barrel closely, ideally with magnification
J BioMed Sci (2014) 21(1):23
